BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences
November 10 2021 - 7:00AM
Business Wire
BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the
“Company”), a clinical-stage biopharmaceutical company developing
novel therapeutics for the treatment of refractory chronic cough
(“RCC”) and other hypersensitization-related disorders, today
announced that Roberto Bellini, BELLUS Health's President and Chief
Executive Officer, will participate in fireside chats at two
upcoming healthcare investor conferences.
Presentation Details:
Event: Jefferies London Healthcare Conference
Date/Time: On-demand starting Thursday, November 18, 2021 at
8:00 a.m. GMT
Event: 4th Annual Evercore ISI HealthCONx Virtual
Conference Date/Time: Wednesday, December 1, 2021 at 11:20
a.m. EST
Webcasts of the Jefferies and Evercore fireside chats may be
accessed on the Events & Presentations page under the Investors
& Media section of BELLUS Health's website at
www.bellushealth.com. Following the events, archived webcasts will
be available on the Company’s website.
About BELLUS Health (www.bellushealth.com)
BELLUS Health is a clinical-stage biopharmaceutical company
developing novel therapeutics for the treatment of RCC and other
hypersensitization-related disorders. The Company's product
candidate, BLU-5937, is being developed for the treatment of RCC
and chronic pruritus associated with AD.
RCC is a cough lasting more than 8 weeks despite appropriate
treatment for underlying condition(s). It is estimated that there
are approximately 9 million patients in the United States suffering
from RCC. RCC is associated with significant adverse physical,
social, and psychosocial effects on health and quality of life.
Currently, there is no specific therapy approved for RCC and
treatment options are limited.
Chronic pruritus associated with AD is an irritating sensation
that leads to scratching and persists for longer than 6 weeks in AD
patients. It is estimated that up to 10% of adults in the United
States suffer from AD – almost all report symptoms of pruritus with
over 50% of patients attributing chronic pruritus as their most
burdensome symptom. Despite currently available treatments
targeting AD, there continues to be a lack of options specifically
targeting the burden of pruritus in patients with AD.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211110005524/en/
FOR MORE INFORMATION: Ramzi Benamar Chief Financial
Officer rbenamar@bellushealth.com
Media: Julia Deutsch Solebury Trout
jdeutsch@soleburytrout.com
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Nov 2024 to Dec 2024
BELLUS Health (TSX:BLU)
Historical Stock Chart
From Dec 2023 to Dec 2024